Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
GSK announced in a press release on 14 November 2022 the positive results of its open-label phase 2a trial of GSK30336656, a first-in-class drug for the treatment of tuberculosis. The molecule functions as an inhibitor of the Mycobacterium tuberculosis enzyme leucyl-tRNA synthetase, blocking protein synthesis. Patients with drug-susceptible pulmonary tuberculosis treated with the investigational drug for 14 days showed a significant, dose-dependent reduction in colony-forming units in their sputum, the trial’s primary endpoint. Andreas Diacon, GSK’s Chief Scientific Officer, stated in the press release that “GSK3036656 is a potential new antibiotic for tuberculosis that can be used in low, once-daily doses. This can help reduce side effects and is an important characteristic of any new tuberculosis drug. GSK3036656 is of a completely new class of antibiotics which makes the chance of drug resistance very low.”